Personal Genome Diagnostics develops regulated tissue-based and liquid biopsy genomic products, including the FDA-cleared elio™ tissue complete kit that enables laboratories to perform comprehensive on-site tumor profiling. The company focuses on decentralized tumor profiling to expand access to genomic information across academic medical centers and community hospitals. PGDx plans to use recent funding to expand its tissue and liquid biopsy portfolio, grow its global commercial footprint, and scale commercial and operational infrastructure. It also aims to broaden adoption of its elio™ oncology products and expand pharma and biotechnology partnerships to accelerate biomarker-driven therapy development. The company was established by researchers from Johns Hopkins University and has secured positive Medicare coverage decisions and several strategic partnership agreements. PGDx recently closed a $103 million Series C financing to support these growth initiatives. Personal Genome Diagnostics (PGDx) is a Baltimore-based developer of tissue-based and liquid biopsy technologies for cancer genomics. The company specializes in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes. It maintains a diversified business model supported by a proprietary technology portfolio, bioinformatics system, and comprehensive genetic library. PGDx was founded in 2010 by Luis Diaz and Victor Velculescu and is led by CEO Douglas Ward. The company intends to use the funds to advance its regulated in vitro diagnostic (IVD) genome testing technologies. The financing is reported as up to $42.0M provided under an agreement with Innovatus Capital Partners. Personal Genome Diagnostics is a Baltimore-based life sciences company focused on tissue-based and liquid biopsy technologies and products for cancer genomics. It specializes in high-throughput next-generation sequencing and proprietary algorithms to identify alterations in complex cancer genomes and has developed non-invasive approaches to cancer testing. PGDx is developing and commercializing a portfolio of tissue and liquid biopsy in vitro diagnostic (IVD) cancer tests that will be clinically validated and regulated to enable worldwide access to its technology. The company intends to use the Series B proceeds to support a strategic initiative to bring regulated IVD genome testing to cancer patients and their physicians worldwide. Led by CEO Douglas Ward, PGDx offers end-to-end cancer genome analysis capabilities from sample preparation and sequencing to data interpretation and analysis. The financing supports the company’s commercialization and regulatory efforts for its IVD test portfolio. Personal Genome Diagnostics (PGDx) develops a platform of advanced genomic analyses for oncology, including whole genome sequencing, pan-cancer panels, targeted panels and single-gene analysis in tissue and liquid biopsies. The company also offers custom approaches for target discovery and companion diagnostics and provides clinical services through its CLIA-certified laboratory. PGDx was founded in 2010 by Johns Hopkins researchers Luis A. Diaz and Victor Velculescu. The company occupies an 11,000-square-foot historic facility in Baltimore’s harbor neighborhood and has 63 employees. PGDx intends to use new funding to expand operations and increase adoption of its services. Personal Genome Diagnostics, founded in 2010 by Luis Diaz, MD, and Victor Velculescu, MD, PhD, develops advanced cancer genome analyses using genomic methods and cancer-biology expertise to identify and characterize tumor genomic alterations. The company provides services and assays to oncology researchers, drug developers, clinicians and patients. It offers circulating tumor DNA assays and is using new funds to support further development and marketing of those assays. Since inception the company has been funded primarily by revenue from its cancer genome analysis services to biopharmaceutical firms, academic research centers, contract research organizations, patients and physicians. The company is based in Baltimore, MD and focuses on translating genomic methods into actionable cancer diagnostics and assays.

Total raised

$244M

Funding rounds

5

Latest round

Series C

Latest activity

Feb 2021